Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Pharmaceutical Preparations

Standard Industrial Classification: SIC 2834

Industry Insider Sentiment Analysis

The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2025-04-15 21:02 2025-04-10 RMTI ROCKWELL MEDICAL, INC. Irrevocable Larson Family Investment Trust 10% owner BUY $1.07 87,500 $94,019 3,557,500
2025-04-14 13:30 2025-04-11 RNXT RenovoRx, Inc. Agah Ramtin Director, Officer BUY $0.80 20,000 $16,000 1,098,460
2025-04-15 01:23 2025-04-11 TVTX Travere Therapeutics, Inc. Cline Christopher R. Officer SELL $13.14 48 $631 89,990
2025-04-14 23:13 2025-04-10 XNCR Xencor Inc Cornelissen Bart Jan Officer SELL $8.06 3,750 $30,233 61,348
2025-04-15 01:57 2025-04-10 RCKT ROCKET PHARMACEUTICALS, INC. Shah Gaurav Director, Officer BUY $5.08 20,000 $101,600 792,680
2025-04-15 00:58 2025-04-10 CORT CORCEPT THERAPEUTICS INC Swisher Daniel N JR Director OPT+S $70.22 2,200 $154,484 0
2025-04-14 23:17 2025-04-14 ANIP Ani Pharmaceuticals Inc. Cook Meredith Officer SELL $68.96 400 $27,584 80,145
2025-04-12 04:45 2025-04-09 OSTX OS Therapies Inc Auerbach Shalom 10% owner SELL $1.36 60,012 $81,568 2,746,199
2025-04-12 01:00 2025-04-10 AKRO Akero Therapeutics, Inc. Cheng Andrew Director, Officer SELL $35.23 30,000 $1,056,780 624,324
2025-04-12 04:57 2025-04-09 KROS Keros Therapeutics, Inc. ADAR1 Capital Management, LLC 10% owner BUY $10.13 934,258 $9,464,501 4,392,737
2025-04-12 01:20 2025-04-09 ARWR Arrowhead Pharmaceuticals Inc. Anzalone Christopher Richard Director, Officer SELL $10.87 141,122 $1,533,333 3,921,255
2025-04-12 00:22 2025-04-09 KALV KalVista Pharmaceuticals, Inc. Venrock Healthcare Capital Partners III, L.P. 10% owner BUY $9.42 25,000 $235,500 5,303,985
2025-04-11 20:23 2025-04-10 GOVX GeoVax Labs, Inc. SPENCER JOHN N JR Director BUY $0.98 10,000 $9,800 11,402
2025-04-12 00:29 2025-04-09 RNAC Cartesian Therapeutics, Inc. SPRINGER TIMOTHY A Director, 10% owner BUY $10.21 149,075 $1,522,518 656,513
2025-04-10 23:29 2025-04-09 TXMD TherapeuticsMD, Inc. Walker Marlan D Officer BUY $0.87 2,303 $1,994 73,149
2025-04-11 01:00 2025-04-07 AKRO Akero Therapeutics, Inc. Rolph Timothy Officer OPT+S $35.88 6,250 $224,261 169,721
2025-04-11 00:17 2025-04-08 RYTM RHYTHM PHARMACEUTICALS, INC. Cramer Pamela J. Officer OPT+S $60.14 20,760 $1,248,490 19,209
2025-04-11 00:16 2025-04-08 RYTM RHYTHM PHARMACEUTICALS, INC. Mazabraud Yann Officer SELL $60.99 17,750 $1,082,498 22,620
2025-04-11 02:02 2025-04-08 RNXT RenovoRx, Inc. Kocak Ron Officer BUY $0.79 12,595 $10,011 12,595
2025-04-10 23:30 2025-04-09 RNXT RenovoRx, Inc. Agah Ramtin Director, Officer BUY $0.81 30,000 $24,399 1,078,460
2025-04-10 13:02 2025-04-09 RNXT RenovoRx, Inc. Bagai Shaun Director, Officer BUY $0.83 10,000 $8,300 312,540
2025-04-10 15:39 2025-04-08 MBX MBX Biosciences, Inc. Pescovitz Ora H. Director BUY $5.89 7,693 $45,312 24,329
2025-04-10 23:01 2025-04-10 GOVX GeoVax Labs, Inc. Sharkey John W. Officer BUY $0.99 6,000 $5,940 6,191
2025-04-10 23:02 2025-04-10 AGIO Agios Pharmaceuticals Inc. FOUSE JACQUALYN A Director OPT+S $25.90 7,497 $194,172 149,220
2025-04-11 00:07 2025-04-10 OPK OPKO HEALTH, INC. FROST PHILLIP MD ET AL Director, Officer, 10% owner BUY $1.36 125,000 $169,713 214,001,448
2025-04-10 23:07 2025-04-09 RCKT ROCKET PHARMACEUTICALS, INC. Patel Kinnari Officer BUY $4.70 21,099 $99,165 26,774
2025-04-11 02:06 2025-04-09 PVLA PALVELLA THERAPEUTICS, INC. JENKINS GEORGE M Director BUY $20.20 4,990 $100,798 13,516
2025-04-10 23:15 2025-04-08 ACUT Accustem Sciences Inc. CERRONE GABRIELE M Director, 10% owner BUY $0.67 38,000 $25,285 4,910,759
2025-04-11 00:40 2025-04-10 CYTK CYTOKINETICS INC Blum Robert I Director, Officer SELL $36.77 5,000 $183,850 422,629
2025-04-09 23:44 2025-04-07 XOMA XOMA Royalty Corp Sitko Bradley Officer BUY $24.70 2,000 $49,400 5,045
2025-04-09 14:40 2025-04-08 PEPG PepGen Inc. McArthur James G Director, Officer BUY $1.15 41,500 $47,725 103,913
2025-04-09 23:25 2025-04-07 ELVN Enliven Therapeutics, Inc. Patel Anish Officer SELL $18.04 6,667 $120,269 316,643
2025-04-10 04:30 2025-04-08 RNXT RenovoRx, Inc. Marton Laurence Director BUY $0.85 12,050 $10,218 45,684
2025-04-09 19:45 2025-04-08 RNXT RenovoRx, Inc. Agah Ramtin Director, Officer BUY $0.84 26,000 $21,840 1,048,460
2025-04-09 04:36 2025-03-26 NTHI NEONC TECHNOLOGIES HOLDINGS, INC. GARNETT KEITHLY Director, Officer SELL $24.85 6,616 $164,425 44,053
2025-04-09 04:36 2025-03-26 NTHI NEONC TECHNOLOGIES HOLDINGS, INC. WALTERS PATRICK Officer SELL $24.85 11,847 $294,431 78,885
2025-04-09 04:35 2025-03-26 NTHI NEONC TECHNOLOGIES HOLDINGS, INC. CHIANG MING-FU (ALAN) Director SELL $24.85 57,696 $1,433,913 384,180
2025-04-09 04:35 2025-03-26 NTHI NEONC TECHNOLOGIES HOLDINGS, INC. CHEN THOMAS C Director, Officer, 10% owner SELL $24.85 39,233 $975,054 261,242
2025-04-08 13:05 2025-04-07 GLSI Greenwich LifeSciences, Inc. Patel Snehal Director, Officer, 10% owner BUY $9.10 3,600 $32,760 5,561,602
2025-04-09 04:52 2025-04-04 VREO Vireo Growth Inc. Chicago Atlantic Credit Opportunities, LLC 10% owner BUY $0.42 60,000 $25,158 11,206,278
2025-04-09 00:30 2025-04-04 OKUR OnKure Therapeutics, Inc. Leverone Jason A. Officer SELL $2.94 3,122 $9,178 13,209
2025-04-09 00:32 2025-04-04 OKUR OnKure Therapeutics, Inc. Saccomano Nicholas A Director, Officer SELL $2.94 874 $2,570 3,682
2025-04-08 18:30 2025-04-07 RNXT RenovoRx, Inc. Bagai Shaun Director, Officer BUY $0.83 10,000 $8,300 302,540
2025-04-08 23:45 2025-04-07 SPRY ARS Pharmaceuticals, Inc. Shawver Laura Director OPT+S $12.30 50,002 $615,075 210,346
2025-04-09 04:36 2025-03-26 NTHI NEONC TECHNOLOGIES HOLDINGS, INC. Heshmatpour Amir F Director SELL $24.85 38,464 $955,942 256,120
2025-04-09 00:34 2025-04-08 OPK OPKO HEALTH, INC. FROST PHILLIP MD ET AL Director, Officer, 10% owner BUY $1.48 125,000 $184,650 213,876,448
2025-04-09 00:01 2025-04-07 PHAT Phathom Pharmaceuticals, Inc. Henderson Molly Officer SELL $4.55 3,678 $16,740 89,868
2025-04-09 02:24 2025-04-04 ARDX Ardelyx Inc. RAAB MICHAEL Director, Officer OPT+S $4.59 41,666 $191,151 1,615,587
2025-04-09 04:30 2025-04-04 NUVB Nuvation Bio Inc. Hung David Director, Officer, 10% owner BUY $1.64 500,000 $820,200 58,781,054
2025-04-08 23:06 2025-04-04 RCKT ROCKET PHARMACEUTICALS, INC. Ondrey Aaron Officer SELL $5.29 7,489 $39,647 129,650
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Pharmaceutical Preparations

Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.